Fundraising FoxEcoR1 Capital — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Neurogene develops gene therapy treatments for rare neurological diseases.
BiotechDeep TechDigital HealthLongevityMedical DevicesNew York, US
Rachel McMinn(Founder and Chief Executive Officer)inRachel McMinn, Ph.D.(Founder and Chief Executive Officer)
BoardCory Freedland(Director)inStephen Biggar(Director)
Co-investorsSamsara BioCapitalCasdin CapitalREDMILERTW Investments L.P.William Blair
Epikast provides AI-powered tools for medical science liaisons and field teams to analyze clinical interactions with physicians and patients, and to access synthesized scientific information in their disease areas.
AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBrooklyn, US
Evangelos Vergetis(Executive Officer, Director)
BoardBrad Prosek(Director)Stelios Papadopoulos(Director)Daphne Karydas(Director)Alexandros Tzoukas(Director)
Board seatOleg Nodelman· per SEC Form D
Co-investorsVedanta Capital
Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.
BiotechDeep TechSouth San Francisco, US
Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)in
BoardMichael Goller(Director)Reid Huber(Director)inPeter Thompson(Director)in
Co-investorsOrbiMedRA CapitalNovo HoldingsThird Rock Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.